Ryan Specialty places and manages specialty insurance, mostly excess and surplus lines and binding authority programs for hard-to-place risks, with its Wholesale Brokerage, Binding Authority and Underwriting Management, and Specialty Benefits segments. The moat is the binding authority model: Ryan holds delegated underwriting authority from carriers, which lets it write and price business quickly and earn fees across the placement chain. Revenue growth of 7.4% and a 22.1% ROE with a 25.0% operating margin put it among the more profitable brokers, though the trailing P/E of 56.4 is inflated by a depressed prior-year earnings base, and the forward P/E of 14.6 is the more relevant gauge. The stock scores 45 of 100 and sits outside major indices, so the case rests on whether specialty pricing and retention hold up as the cycle softens. That is worth a deeper look mainly to test the durability of organic growth against a rate environment that is starting to normalize.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 18 Oct 2026, 00:00 CEST | Fair value | $23.31 | $23.01 | $40.75 |
| 14 Oct 2026, 00:00 CEST | Fair value | $23.01 | $5.36 | $37.25 |
| 10 Oct 2026, 00:00 CEST | ACCE price target | $41.00 | first publication | $37.79 |
| 9 Oct 2026, 00:00 CEST | Fair value | $5.36 | $5.48 | $37.60 |
| 29 Sept 2026, 00:00 CEST | Fair value | $5.48 | $5.65 | $37.89 |
| 21 Sept 2026, 00:00 CEST | Fair value | $5.65 | $5.77 | $40.27 |
| 18 Sept 2026, 00:00 CEST | Fair value | $5.77 | $5.66 | $40.29 |
| 10 Sept 2026, 00:00 CEST | Fair value | $5.66 | $5.79 | $40.87 |
| 7 Sept 2026, 00:00 CEST | Fair value | $5.79 | $4.23 | $41.91 |
| 5 Sept 2026, 00:00 CEST | Fair value | $4.23 | $4.10 | $42.34 |
Answered from Ryan Specialty Holdings Inc. Class A Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| RYAN Ryan Specialty Holdings Inc. Class A Common Stock | $43.68 | $23 | 87% above | 61.5x | 22.1% | 64 | 52 |
| ERIE Erie Indemnity Company Class A Common Stock | $253.52 | $143 | 77% above | 23.0x | 24.8% | 70 | 48 |
| BRO Brown & Brown Inc. Common Stock | $72.97 | $60 | 21% above | 23.5x | 10.0% | 74 | 71 |
| POLICYBZR.NS PB Fintech Limited | ₹1015.00 | - | - | 61.3x | - | 76 | 52 |
| SDF.AX Steadfast Group Limited | A$5.81 | A$5 | 15% above | 24.2x | 12.4% | 74 | 55 |
| BWIN The Baldwin Insurance Group Inc. Class A Common Stock | $31.96 | - | - | - | -10.7% | 25 | 56 |
| ARX Accelerant Holdings Class A Common Shares | $19.77 | $23 | 13% below | - | -222.0% | 60 | 75 |
Where RYAN ranks against its sector peers on each metric.